

1 Acellular Urethra Bioscaffold: Decellularization of Whole  
2 Urethras for Tissue Engineering Applications

3 IRINA N. SIMÕES<sup>a,b,c</sup>, PAULO VALE<sup>d</sup>, SHAY SOKER<sup>b</sup>, ANTHONY ATALA<sup>b</sup>,  
4 DANIEL KELLER<sup>c</sup>, RUTE NOIVA<sup>e</sup>, SANDRA CARVALHO<sup>e</sup>, CONCEIÇÃO  
5 PELETEIRO<sup>e</sup>, JOAQUIM M. S. CABRAL<sup>a</sup>, DANIEL EBERLI<sup>c</sup>, CLÁUDIA L. DA  
6 SILVA<sup>a</sup> AND \*PEDRO M. BAPTISTA<sup>b,f,g</sup>

7 <sup>a</sup>Department of Bioengineering and IBB - Institute for Bioengineering and Biosciences, Instituto  
8 Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais 1, 1049-001 Lisboa, Portugal,  
9 <sup>b</sup>Wake Forest Institute for Regenerative Medicine, 391 Technology Way NE Winston-Salem, NC  
10 27101, USA, <sup>c</sup>Laboratory for Tissue Engineering and Stem Cell Therapy, Department of  
11 Urology, University Hospital Zurich, Zurich, Switzerland, <sup>d</sup>Serviço Urologia, Hospital Garcia de  
12 Orta, Av. Torrado da Silva 2801-951, Almada, Portugal, <sup>e</sup>Faculdade de Medicina Veterinária,  
13 The Interdisciplinary Centre of Research in Animal Health (CIISA), Universidade de Lisboa,  
14 Avenida Universidade Técnica, 1300-477 Lisboa, Portugal, <sup>f</sup>IIS Aragón, CIBERehd, Zaragoza,  
15 Spain and <sup>g</sup>Instituto Aragonés de Ciencias de la Salud, Centro de Investigación Biomédica de  
16 Aragón, Av. San Juan Bosco 13, 50009 Zaragoza, Spain

17

18 Corresponding Author:

19 Pedro M. Baptista

20 Instituto Investigación Sanitaria de Aragón (IIS Aragón)

21 Centro de Investigación Biomédica de Aragón

22 Avenida San Juan Bosco, 13

23 50009 Zaragoza, Spain

24 E-mail: [pbaptista.iacs@aragon.es](mailto:pbaptista.iacs@aragon.es); [pmbaptista1976@gmail.com](mailto:pmbaptista1976@gmail.com)


25

26

27


28

29 **Supplementary Figures**



30

31 **Supplementary Figure S1. Urethra anatomy.** (a) Schematic representation of the anatomical  
32 structure of male and female urethra (b) and cross-sectional organization of muscle (●, smooth  
33 and ★, skeletal or RBS) and mucosal (◇) tissues in the urethra. Scale bar: 100µm. Image  
34 obtained through H&E staining.



35


36 **Supplementary Figure S2. Decellularization apparatus based on mechanochemical**  
37 **action.** Detergent solution (or distilled water) was placed inside the (a) vessel, where the (b)  
38 urethra was submerged. The solution was pumped by a (c) peristaltic pump and recircularized  
39 at a rate of 40 mL/min. Through a (d) magnetic stirrer plate the solution was (e) agitated at  
40 60rpm. The process was repeated for 5 days. By the end of the first 48h, the direction of  
41 perfusion was changed (from the black arrows to the grey arrows) to allow a more efficient  
42 decellularization.

43

44


45

46




47

48 **Supplementary Figure S3. Microdissection of the urethra bioscaffolds to prepare**  
 49 **sections with different muscle ECMs.** (a) Microdissection was performed under a stereo  
 50 microscope and the bioscaffold was pinned on a gelatin coated plate. (b-c) RBS (\*) was  
 51 detached from the smooth muscle layer (●) and (d) skECM and (e) smECM sections,  
 52 respectively were produced. Scale bar: 1 cm.



53


54 **Supplementary Figure S4. H&E staining of urethras exposed to decellularization.** (a) 1%  
 55 Triton X-100, (b) 5% Triton X-100 and (c) 0.1% SDS did not decellularize the urethras. Images  
 56 are from 5  $\mu$ m thick sections (\*, muscle and ●, mucosa). Scale bar: 100  $\mu$ m.



57

58 **Supplementary Figure S5. DAPI staining of decellularized urethra bioscaffolds.** Images


59 are centred on the RBS layer. Images are from 5  $\mu\text{m}$  thick sections. Scale bar: 100  $\mu\text{m}$ .



60

61 **Supplementary Figure S6. SEM of decellularized urethra bioscaffolds.** Longitudinal and

62 transversal cuts of native urethra and 0.5% decellularized bioscaffold.




63


64 **Supplementary Figure S7. MPCs (ZenBio®) fiber formation *in vitro*.** Cells changed their

65 morphology after exposure to the differentiation medium at (a) days 0 and (b) 3. Between (c-d)

66 days 10 and 12 cells fused and produce multinucleated fibers (black arrows). Fibers expressed  
67 (e) desmin and (f) myosin heavy chain while showing no (g) Pax3 and (h) MyoD. Nuclei were  
68 stained with DAPI (in blue). Scale bar: 50  $\mu$ m.




69  
70 **Supplementary Figure S8. MPCs (isolated at USZ) *in vitro* fiber formation.** After (a-b) 14  
71 days in culture, MPCs fused and produced multinucleated fibers (black arrows) while  
72 demonstrating (c) viability through calcein AM staining and the expression of (d) desmin, (e)  $\alpha$ -  
73 actinin and (f) MyHC (all in red) through immunofluorescence staining. Nuclei were stained with  
74 DAPI (in blue). Scale bar: 50  $\mu$ m.



75

76 **Supplementary Figure S9. Recellularization of urethra bioscaffolds with SVF populations.**


77 Cultures were performed using (a-f) DMEM + 10%FBS or (g-k) DMEM + 2% HS. Presence of (a  
78 and g) α-actin, (b and h) calponin, (c and i) MyoD, (d and j) MyHC, (e) CD31 and (f and k)  
79 vimentin was assessed through immunohistochemistry. Scale bar: 100 μm.



80

81 **Supplementary Figure S10. Cell viability and proliferation on urethra ECM coatings. (a-h)**

82 Cell viability was assessed using Calcein AM staining. Scale bar: 150 μm. (i) Cell proliferation  
83 was assessed using WST-1 assay (Roche) at 450 nm in relation to MPCs grown in non-coated-  
84 polystyrene: skECM (green), smECM (blue) and FBS (yellow) coatings. Results as mean ± SEM  
85 (n=3), p > 0.05 for all time points, ANOVA.



86

87 **Supplementary Figure S11. Expression of skeletal muscle-related genes in MPCs on**

88 **urethra ECM coatings.** The expression of desmin, MyHC and α-actinin genes was quantified

89 through RT-qPCR on MPCs after 14 days of differentiation in non-coated polystyrene (grey),

90 FBS (yellow), skECM (green) and smECM (blue). Dashed line marks the expression of the gene

91 in the reference condition, non-coated polystyrene (grey). Results as mean ± SEM (n=3), p >

92 0.05 for all conditions, ANOVA.

93

94 **Supplementary Table S1.** Data for the estimation of the pressure (P) to which the urethra is

95 subjected with the perfusion decellularization method.

14 Gauge Internal Diameter	0.0016 m
14 Gauge Length	0.0450 m
Area	2.01x10 <sup>-6</sup> m <sup>2</sup>
ρ Water	1000 Kg/m <sup>3</sup>
ρ Triton X-100	1070 Kg/m <sup>3</sup>
ρ SDS	1030 Kg/m <sup>3</sup>
Flow Rate (Q)	6.67x10 <sup>-7</sup> m <sup>3</sup> /s
Velocity (V)	0.33 m/s

96

97 **Supplementary Table S2.** Macroscopic assessment of the outcome of the decellularization

98 process using each detergent solution tested (+ for positive decellularization, organ become

99 white/transparent; – for negative decellularization, organ did not become white/transparent).

Decellularization Solution	Results
1% Triton X-100 + 0.1% NH <sub>4</sub> OH	-
5% Triton X-100 + 0.5% NH <sub>4</sub> OH	-
0.1% SDS	-
0.5% SDS	+
1% SDS	+

100

101 **Supplementary Video S1. MPCs fiber formation *in vitro*.** After 12 days of induction MPCs  
102 started to contract. Scale bar: 100 µm. Time frame: 9 seconds.

103

## 104 **Supplementary Methods**

### 105 **Decellularization of Urethra Tissue – DAPI Staining**

106 Five µm thick sections of native (n=4) and decellularized (n=5, 0.5% SDS and n=2, 1% SDS)  
107 urethras processed for DAPI staining. DAPI (1:100, Sigma®) was incubated for 1 h at room  
108 temperature. Slides were mounted with ProLong® Gold Antifade (Invitrogen™). Images were  
109 captured on a Leica Microsystems DM4000B upright microscope (Leica Microsystems Inc.,  
110 Wetzlar, Germany) with Image-Pro® Express software (Media Cybernetics Inc., Rockville, MD,  
111 USA).

112

### 113 **Isolation, Expansion and Differentiation of Cells for Recellularization and Seeding**

#### 114 **Muscle Progenitor Cells (MPCs)**

115 MPCs were purchased (Zenbio®) or isolated from muscle tissue obtained from healthy donors  
116 after informed consent at USZ in Switzerland<sup>25</sup>. MPCs from Zenbio® were plated at 5000  
117 cells/cm<sup>2</sup> and expanded using SkMGM (ZenBio®) for at least two cell passages. MPCs isolated  
118 at USZ were plated at 5000 cells/cm<sup>2</sup> and expanded for at least one cell passage using growth  
119 medium DMEM/F12 (Gibco®) supplemented with 18% FBS (Gibco®), 10 ng/ml hEGF  
120 (Sigma®), 1 ng/ml hbFGF (Sigma®), 10 µg/ml human insulin (Sigma®) and 0.4 µg/ml  
121 dexamethasone (Sigma®).

#### 122 **Stromal Vascular Fractions (SVF)**

123 SVF were isolated from discarded liposuctions of healthy donors after informed consent at  
124 “Clínica de Todos-Os-Santos” in Lisbon, Portugal using a standard enzymatic protocol<sup>26</sup>. SVF  
125 populations were immediately used for recellularization.

#### 126 **Bone Marrow Mesenchymal/Stromal Stem Cells (BM MSCs) and Fibroblasts**

127 BM MSC were isolated from bone marrow aspirates obtained from healthy donors at Instituto  
128 Português de Oncologia Francisco Gentil in Lisbon, Portugal (IPOFG-L), after informed consent  
129 from an approved protocol by the Ethical Review Board of IPOFG-L<sup>27</sup>. BM MSC and mouse



130 L929 fibroblasts (Leibniz-Institute DSMZ) were plated at 3000 cells/cm<sup>2</sup> and expanded using  
131 DMEM + 10% FBS for at least one cell passage. All cultures were maintained at 37°C and 5%  
132 CO<sub>2</sub> with medium changes every 3-4 days.

133

#### 134 **Microdissection of Urethra Bioscaffolds**

135 The RBS layer of whole decellularized urethras (n=4) was isolated from the remaining  
136 bioscaffold through microdissection (Supplementary Figure S3). Transversal fragments of the  
137 area containing the RBS layer were cut and pinned on gelatin-coated plates. Microdissection  
138 was carried out under stereo microscope (Supplementary Figure S3a, Zeiss Stemi 2000-c, Carl  
139 Zeiss©) and using a Zeiss KL1500 LCD cold light source (Carl Zeiss©). A small incision was  
140 made on the most external layer of the bioscaffold (Supplementary Figure S3b) using a  
141 disposable scalpel. The RBS was detached from the remaining bioscaffold using the blunt end  
142 of the scalpel (Supplementary Figure S3c), creating two bioscaffolds – skECM (skeletal muscle  
143 ECM, Supplementary Figure S3d) and smECM (smooth muscle ECM, Supplementary Figure  
144 S3e).

145

#### 146 **MPCs Fiber Formation**

147 Fiber formation was induced using DMEM/F12 + 10% FBS (Gibco®) (DMEM + 2% HS (Gibco®)  
148 for the MPCs from Zenbio®) for 14 days at 37°C and 5% CO<sub>2</sub> with medium changes every 3  
149 days. Fiber formation was confirmed through immunofluorescence staining using anti-desmin  
150 (1:50, Sigma©), anti-Pax3 (1:100, Santa Cruz Biotech.), anti-MyoD (1:100, BD Biosciences),  
151 anti- $\alpha$ -actinin (1:500, Sigma©) and anti-MyHC (1:1, DSHB, University of Iowa, IO, USA).  
152 Secondary antibodies FITC-conjugated goat anti-mouse (Abcam®, Cambridge, UK), FITC-  
153 conjugated donkey anti-goat, Alexa-546-conjugated goat anti-mouse, Alexa-546-conjugated  
154 goat anti-rabbit (all 1:500, all from Invitrogen™) and Cy3-conjugated sheep anti-mouse (1:1000,  
155 Sigma©) were used. Cell nuclei were counterstained using DAPI (1:10000, Sigma®). For Pax3  
156 staining all solutions were prepared using FBS instead of NGS. Images were acquired using  
157 Leica DM6000 B fluorescence microscope and the LAS AF software both from Leica  
158 Microsystems Inc.

159

160 **Cell Viability Analysis**

161 Cultures were washed with PBS and incubated in culture medium containing Calcein AM  
162 (1:1000, Sigma©) for 30 min. Images were acquired using Leica DM6000 B fluorescence  
163 microscope and the LAS AF software both from Leica Microsystems Inc.

164

165 **RT-qPCR**

166 Total RNA was isolated with SV Total RNA Isolation System Kit (Promega) according to  
167 manufacturer's instructions. RNA concentration was determined through spectrophotometry at  
168 260 nm using NanoDrop Lite (Thermo-Scientific™). RNA was reverse transcribed with random  
169 primers using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems™) and  
170 the T3000 Thermocycler (Biometra). Pre-designed primers for human desmin, MyHC1, MyHC2  
171 and  $\alpha$ -actinin were purchased from Life Technologies™. The analysis was normalized to the  
172 endogeneous gene S18. Real Time quantitative Polymerase Chain Reaction (RT-qPCR) was  
173 performed using RotorGene RG3000 and data was acquired using RotorGene software (both  
174 from CR Corbett Research). RT-qPCR was performed based on TaqMan assay, TaqMan Fast  
175 Advanced Master Mix (Applied Biosystems™). Detection was made with Fluorophor FAM and  
176 wavelength of 495 nm. The expression fold of each gene was calculated using Supplementary  
177 Equation (S1), where  $\Delta Ct$  is the  $C_{target} - C_{endogenous}$  ( $C_t$ , threshold cycle). The cultures using non-  
178 coated polystyrene were used as the reference condition for all calculations.

179

$$Expression\ Fold = 2^{-(\Delta Ct_{target} - \Delta Ct_{reference})} \quad \text{Supplementary Equation (S1)}$$